<DOC>
	<DOCNO>NCT00689702</DOCNO>
	<brief_summary>This nonrandomised pilot trial establish role intravenous cetuximab add schedule capecitabine plus pelvic radiation patient locally advance primary resectable rectal cancer .</brief_summary>
	<brief_title>Cetuximab ( ErbituxÂ® ) , Capecitabine Radiotherapy Neoadjuvant Treatment Patients With Rectal Cancer</brief_title>
	<detailed_description>Preoperative radiotherapy 5-FU base chemotherapy , along complete resection mesorectum standard treatment locally advance rectal cancer.Capecitabine potential replace 5-FU standard agent . Cetuximab monoclonal antibody direct EGFR . Both agent active treatment colorectal cancer demonstrate radiosensitising properties.The trial aim assess efficacy , safety toxicity combination cetuximab , capecitabine radiation patient stage II III rectal cancer .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age 18 80 judged fit surgery WHO performance status 01 Histologically proven rectal adenocarcinoma locate peritoneum T3T4 or/and nodal involvement determine rectal ultrasound compute tomography ( CT ) MRI No distant metastasis Adequate haematological , cardiac , liver renal function Signed informed consent Appropriate measure contraception men woman , applicable Prior radio and/or chemotherapy Others synchronous cancer History malignant disease Significant heart disease Known hypersensitivity biological drug Pregnant lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>rectal cancer</keyword>
</DOC>